Publications by authors named "E E Dumbrava"
Here we report results of a phase 1 multi-institutional, open-label, dose-escalation trial (NCT02744287) of BPX-601, an investigational autologous PSCA-directed GoCAR-T® cell product containing an inducible MyD88/CD40 ON-switch responsive to the activating dimerizer rimiducid, in patients with metastatic pancreatic (mPDAC) or castration-resistant prostate cancer (mCRPC). Primary objectives were to evaluate safety and tolerability and determine the recommended phase 2 dose/schedule (RP2D). Secondary objectives included the assessment of efficacy and characterization of the pharmacokinetics of rimiducid.
View Article and Find Full Text PDFImmune checkpoint blockade targeting the novel targets of the lymphocyte activation gene 3 (LAG3) and the T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibition motif domains (TIGIT) has marked a significant advancement in oncology, offering new therapeutic opportunities to fight diverse malignancies. This review covers the biological basis and clinical application of LAG3 and TIGIT inhibitors, highlighting pivotal trials and therapeutic outcomes. We underscore the use of dual therapy immune checkpoint blockade in enhancing antitumor immunity, particularly in settings where monotherapy has shown limited efficacy.
View Article and Find Full Text PDFPurpose: Treatment options for advanced head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and a programmed death-1 (PD-1) inhibitor are limited. Trophoblast cell-surface antigen 2 (Trop-2) is highly expressed in HNSCC. Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate approved for patients with certain previously treated solid tumors.
View Article and Find Full Text PDFArticle Synopsis
- PD-1 inhibition shows effectiveness in treating patients with mismatch repair deficient (dMMR) solid tumors; however, routine testing for dMMR using immunohistochemistry (IHC) is not common across different tumor types.
- A study involving over 15,000 solid tumor patients demonstrated that next-generation sequencing (NGS) can help identify mutations in MMR genes, revealing a correlation with IHC results in those tested.
- The findings indicate that patients with MMR mutations showed a significant rate of dMMR, highlighting the potential benefits of employing IHC testing on patients with identified MMR mutations to optimize treatment options.